Invesco NASDAQ Biotechnology ETF
IBBQ

$24.43

0.93%

Market Cap: $38.4M

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

1.39% less ownership

Funds ownership: 37.06% [Q1] → 35.67% (-1.39%) [Q2]

9% less capital invested

Capital invested by funds: $10.9M [Q1] → $9.93M (-$999K) [Q2]

12% less funds holding

Funds holding: 17 [Q1] → 15 (-2) [Q2]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for IBBQ.

See Analyst Rankings

Financial journalist opinion

Biotech Rally in Its Early Innings

Following a multiyear run of disappointment, biotech stocks and related ETFs are showing signs of life. For the past 90 days ending February 29, the widely observed Nasdaq Biotechnology Index was higher by almost 17%.

Biotech Rally in Its Early Innings

Zacks Investment Research

6 Factors to Bet on Wall Street: ETFs to Buy

The Nasdaq Composite and the S&P 500 hit new all-time high Friday. However, there are chances of further rally.

6 Factors to Bet on Wall Street: ETFs to Buy

Zacks Investment Research

Biotech ETFs Stage Solid Comeback at the Start of 2024

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Biotech ETFs Stage Solid Comeback at the Start of 2024

Zacks Investment Research

5 Top-Ranked ETF Winners of December With More Room for Gains

Wall Street witnessed an upbeat December due to moderation in inflationary pressures, the likelihood of Fed rate cuts in 2024 and decent corporate earnings.

5 Top-Ranked ETF Winners of December With More Room for Gains

See News Rankings